

First reports of adverse drug reactions

© Springer Nature Switzerland AG 2020

Table 1 contains an overview of first published case reports of adverse drug reactions and interactions identified in the international literature in recent weeks by *Reactions Weekly*, the Adis drug safety newsletter. *Reactions Weekly* provides

summaries of adverse drug reaction news sourced from journals, scientific meetings, media releases, regulatory agency websites, and bulletins from the National Centers that participate in the WHO International Drug Monitoring Programme.

Table 1 First reports of adverse drug reactions and interactions

Drug: adverse reaction	References
Bupropion: spontaneous ejaculation	Uvais NA, et al. Bupropion-induced spontaneous ejaculations. <i>Prim Care Companion CNS Disord.</i> 2020 2;22(1):19102453.
Cabozantinib: atypical posterior reversible encephalopathy syndrome (serious)	Patwari A, et al. Atypical posterior reversible encephalopathy syndrome due to oral tyrosine kinase inhibitor cabozantinib: first case report. <i>Case Rep Oncol</i> 2020;13(2):1013-19
Certolizumab pegol: hypocomplementemic urticarial vasculitis (serious)	Horai Y, et al. Development of hypocomplementemic urticarial vasculitis during certolizumab pegol treatment for rheumatoid arthritis: a case report. <i>J Clin Pharm Ther.</i> 2020;45(5):1179-92
Entecavir: lichenoid drug eruption (serious)	Cheong XK, et al. "black box warning" rash with entecavir: case report. <i>BMC Gastroenterol.</i> 2020;20(1):305
Methylprednisolone/pyridostigmine: globe subluxation (serious)	Dam J, et al. Globe subluxation following long-term high-dose steroid treatment for myasthenia gravis. <i>Case Rep Ophthalmol.</i> 2020;11(3):534-9
Montelukast: diffuse alveolar haemorrhage (serious)	Martinez Montalvo CM, et al. Montelukast-induced alveolar hemorrhage: report of a case [in Spanish]. <i>Acta Medica Peruana.</i> 2020;37(2):198-203
Natalizumab: measles following measles/mumps/rubella vaccine (serious)	Miauton A, et al. Vaccine-associated measles in a patient treated with natalizumab: a case report. <i>BMC Infect Dis.</i> 2020;20(1):75
Ocrelizumab: dermatographism	Raynowska J, et al. Dermatographism associated with ocrelizumab. <i>Mult Scler Relat Disord.</i> 2020;46:102505
Osimertinib: dermatopathic lymphadenopathy (serious)	Kunimasa K, et al. Dermatopathic lymphadenopathy mimicking disease progression during osimertinib treatment. <i>J Thorac Oncol.</i> 2020;15(10):e178-e180
Pantoprazole: drug-induced hypersensitivity in the form of enterocolitis (serious)	Bouvette G, et al. Drug-induced enterocolitis syndrome (DIES) with pantoprazole in an adult patient. <i>J Allergy Clin Immunol Pract.</i> 2020;9(8):3183-4
<i>Serenoa repens</i> : fixed-drug eruptions	Gammoudi R, et al. Fixed drug eruption to <i>Serenoa repens</i> : first case report and consideration of the use of herbal medicine. <i>Dermatol Ther.</i> 2020. doi/10.1111/dth.14247
Sodium polystyrene sulfonate: rectovaginal fistula (serious)	Martin LE, et al. Rectovaginal fistula induced by Resonium A: first case report and literature review. <i>ANZ J Surg.</i> 2019;89(11):E550-E551
Ulixertinib: retinopathy (serious)	Sioufi K, et al. A case of extracellular signal-regulated kinase inhibitor-associated retinopathy. <i>JAMA Ophthalmol.</i> 2020;138(9):1002-4

An event is serious (US FDA MedWatch definition) when the patient outcome is death, life threatening, hospitalization, disability, congenital anomaly or requires intervention to prevent permanent impairment or damage